Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. They represent a huge step forward in research because they target a known cause of the disease, ...

Drug maker Shanghai Henlius traces its history to 1992, when four ambitious young entrepreneurs formed Fosun Group to seize ...

Two drugs to treat Alzheimer’s disease have been rejected for use on the NHS because their benefits are “too small” to ...

Faster, cheaper, better protein sensing would assist scientists in searching for specific proteins in potential sources for ...

Two drugs to treat Alzheimer’s disease have been rejected for use on the NHS because their benefits are “too small” to justify their cost, the health spending watchdog has said.

Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatme ...

John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.

A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...

FDA's plan to phase out animal testing may hurt Charles River's revenues. The DCF model suggests that CRL presents an ...

BOSTON and LONDON, June 18, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates ...